ClinicalTrials.govpublic full text
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
metastatic breast cancer, breast cancer, her2-negative, her2-low, trastuzumab deruxtecan, t-dxd, ds-8201a, destiny-breast08, anti-her2 antibody drug conjugate (adc), triple-negative breast cancer (tnbc), interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 855003
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.